Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 2:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 99 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Healthy Japanese Volunteers Clear all

Completed Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Dose Study to Assess Blood and Urine Drug Levels of Fostamatinib in Healthy Japanese Subjects

NCT01608542

View directory record Official record

Conditions: Healthy Japanese Volunteers
Interventions: Fostamatinib 100mg, Fostamatinib 200mg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 20 Years to 45 Years

Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Source: ClinicalTrials.gov public record

Updated Dec 18, 2012 · Synced May 22, 2026, 2:46 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate Safety, Tolerability & PK of rhNGF in Healthy Volunteers

NCT03836859

View directory record Official record

Conditions: Healthy Volunteers
Interventions: rhNGF 20μg/mL, Placebo; Drug · Other
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 18 Years to 60 Years

Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Cypress, California

Source: ClinicalTrials.gov public record

Updated Dec 25, 2023 · Synced May 22, 2026, 2:46 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1617 in Healthy Adult Non-Asian and Japanese Subjects Including Assessment of a Food Effect

NCT04077879

View directory record Official record

Conditions: Healthy Volunteers
Interventions: ASP1617, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Glendale, California

Source: ClinicalTrials.gov public record

Updated Oct 22, 2024 · Synced May 22, 2026, 2:46 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants

NCT05148481

View directory record Official record

Conditions: Healthy Volunteer
Interventions: BIIB104, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years · Male only

Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Anaheim, California

Source: ClinicalTrials.gov public record

Updated Apr 17, 2023 · Synced May 22, 2026, 2:46 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Investigate Palbociclib (PD-0332991) Pharmacokinetics In Healthy Subjects Of Japanese Descent Relative To Healthy Non-Asian Subjects, And To Determine If Changes In Palbociclib Dose Result In Proportional Changes In Palbociclib Plasma Exposure In Japanese Subjects

NCT02059330

View directory record Official record

Conditions: Healthy
Interventions: Palbociclib 75mg, Palbociclib 125mg, Palbociclib 100mg, Palbociclib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Source: ClinicalTrials.gov public record

Updated Jun 23, 2014 · Synced May 22, 2026, 2:46 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Study to Compare the Level of Elafibranor in Blood After Repeat Administration in Japanese and Non-Asian Healthy Participants

NCT05543369

View directory record Official record

Conditions: Healthy Volunteers
Interventions: Elafibranor; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Long Beach, California • Los Alamitos, California

Source: ClinicalTrials.gov public record

Updated Feb 19, 2025 · Synced May 22, 2026, 2:46 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Xerecept Intravenous Dose Escalation in Japanese and Caucasian Volunteers

NCT00820092

View directory record Official record

Conditions: Edema
Interventions: Xerecept 1.0, Xerecept 2.0, Xerecept 3.0; Drug
Lead sponsor: Celtic Pharma Development Services; Industry
Eligibility: 20 Years to 45 Years

Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Cypress, California

Source: ClinicalTrials.gov public record

Updated Jul 29, 2013 · Synced May 22, 2026, 2:46 AM EDT

Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Food on the Bioavailability of AJ201, and Safety, Tolerability, and Pharmacokinetics of AJ201 in Japanese and White Healthy Male Participants

NCT07549919

View directory record Official record

Conditions: Healthy Male Adults, Food Effect in Healthy Volunteers
Interventions: AJ201; Drug
Lead sponsor: AnnJi Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years · Male only

Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Los Alamitos, California

Source: ClinicalTrials.gov public record

Updated Apr 23, 2026 · Synced May 22, 2026, 2:46 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate AG-881 in Healthy Japanese and Non-Asian Participants

NCT04145128

View directory record Official record

Conditions: Healthy Volunteers
Interventions: AG881; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Cypress, California

Source: ClinicalTrials.gov public record

Updated Apr 1, 2020 · Synced May 22, 2026, 2:46 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Efficacy of Latanoprostene Bunod in Lowering Intraocular Pressure in Japanese Healthy Male Volunteers

NCT01895985

View directory record Official record

Conditions: Intraocular Pressure
Interventions: Latanoprostene bunod; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 20 Years and older · Male only

Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Madison, New Jersey

Source: ClinicalTrials.gov public record

Updated May 14, 2018 · Synced May 22, 2026, 2:46 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

AZD7325 Single Ascending Dose Study in Healthy Male Japanese Subjects

NCT00769899

View directory record Official record

Conditions: Healthy Volunteer
Interventions: AZD7325, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 20 Years to 50 Years · Male only

Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Source: ClinicalTrials.gov public record

Updated Mar 17, 2009 · Synced May 22, 2026, 2:46 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Single Dose Inclacumab in Japanese Healthy Volunteers Compared to Caucasian Healthy Volunteers

NCT01815827

View directory record Official record

Conditions: Healthy Volunteer
Interventions: inclacumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Anaheim, California

Source: ClinicalTrials.gov public record

Updated Nov 1, 2016 · Synced May 22, 2026, 2:46 AM EDT

Terminated Phase 1 Interventional Accepts healthy volunteers

A Study To Investigate Safety, Tolerability, And Pharmacokinetics Of PF-00868554 In Japanese Healthy Adult Volunteers

NCT00875628

View directory record Official record

Conditions: Healthy Volunteers
Interventions: PF-00868554 or Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Glendale, California

Source: ClinicalTrials.gov public record

Updated Oct 21, 2009 · Synced May 22, 2026, 2:46 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Randomized, Crossover Safety and Pharmacokinetics Study of PT010

NCT02197975

View directory record Official record

Conditions: COPD
Interventions: PT010 Dose 1, PT010 Dose 2, Placebo MDI; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Source: ClinicalTrials.gov public record

Updated Oct 27, 2014 · Synced May 22, 2026, 2:46 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics (PK) of Rilzabrutinib (PRN1008) in Healthy Japanese and Caucasian Subjects

NCT06444191

View directory record Official record

Conditions: Healthy Volunteers
Interventions: Rilzabrutinib; Drug
Lead sponsor: Principia Biopharma, a Sanofi Company; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Glendale, California

Source: ClinicalTrials.gov public record

Updated Jun 4, 2024 · Synced May 22, 2026, 2:46 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

PK and Safety Study of AG-221 in Healthy Male Japanese Subjects and Healthy Male Caucasian Subjects

NCT02387866

View directory record Official record

Conditions: Healthy
Interventions: AG-221; Drug
Lead sponsor: Celgene; Industry
Eligibility: 20 Years to 50 Years · Male only

Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Glendale, California

Source: ClinicalTrials.gov public record

Updated Oct 29, 2018 · Synced May 22, 2026, 2:46 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Caplacizumab Single and Multiple Dose Study in Healthy Japanese and White Subjects.

NCT03172208

View directory record Official record

Conditions: Healthy Volunteers
Interventions: Caplacizumab Dose 1 iv (single-dose), Caplacizumab Dose 2 iv (single-dose), Caplacizumab Dose 2 sc (single-dose), Caplacizumab Dose 2 sc (multiple-dose), Placebo iv (single-dose), Placebo sc (single-dose), Placebo sc (multiple-dose); Biological · Other
Lead sponsor: Ablynx, a Sanofi company; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Glendale, California

Source: ClinicalTrials.gov public record

Updated Nov 13, 2017 · Synced May 22, 2026, 2:46 AM EDT

Completed No phase listed Observational

Identification of Donors of CD36-Deficient Platelets Among Japanese Individuals on the NIH Campus

NCT00015639

View directory record Official record

Conditions: Thrombocytopenia
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Not listed

Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Source: ClinicalTrials.gov public record

Updated Mar 3, 2008 · Synced May 22, 2026, 2:46 AM EDT

Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Pharmacokinetics, Safety, and Tolerability of ABBV-903 in Healthy Japanese and Han Chinese Participants

NCT06009237

View directory record Official record

Conditions: Healthy Volunteers
Interventions: ABBV-903, Placebo for ABBV-903; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Anaheim, California

Source: ClinicalTrials.gov public record

Updated Nov 12, 2023 · Synced May 22, 2026, 2:46 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2495655 in Healthy Subjects

NCT01341470

View directory record Official record

Conditions: Healthy Volunteer
Interventions: LY2495655, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 24 Years to 85 Years

Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Honolulu, Hawaii

Source: ClinicalTrials.gov public record

Updated Jun 16, 2019 · Synced May 22, 2026, 2:46 AM EDT

Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.

NCT07514260

View directory record Official record

Conditions: Healthy Volunteer
Interventions: ABBV-295, Placebo for ABBV-295; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Anaheim, California

Source: ClinicalTrials.gov public record

Updated Apr 14, 2026 · Synced May 22, 2026, 2:46 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study of RO5024048 in Japanese and Caucasian Healthy Volunteers

NCT01152671

View directory record Official record

Conditions: Healthy Volunteer
Interventions: Placebo, RO5024048; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 20 Years to 55 Years

Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 2
States / cities: Glendale, California • Eatontown, New Jersey

Source: ClinicalTrials.gov public record

Updated Nov 1, 2016 · Synced May 22, 2026, 2:46 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 in Japanese and Chinese Healthy Volunteers..

NCT05955183

View directory record Official record

Conditions: Healthy Participants
Interventions: AZD5055, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Glendale, California

Source: ClinicalTrials.gov public record

Updated Dec 7, 2023 · Synced May 22, 2026, 2:46 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Pharmacokinetics, Safety, and Tolerability of Atumelnant in Healthy Japanese and Caucasian Participants

NCT07221084

View directory record Official record

Conditions: Healthy Volunteers
Interventions: Atumelnant, Placebo; Drug
Lead sponsor: Crinetics Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Glendale, California

Source: ClinicalTrials.gov public record

Updated Mar 10, 2026 · Synced May 22, 2026, 2:46 AM EDT